Waters has obtained a non-exclusive license to the technology, which allows researchers to create internal standard calibration curves for their assays.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Having gained traction for its technology in the RUO and LDT spaces, the company is now looking to develop its reagents for use in regulatory-cleared IVDs.
NEW YORK (GenomeWeb) – Precision Antibody in partnership with SISCAPA Assay Technologies has completed a Phase I SBIR contract from the National Cancer Institute to develop antibodies for mass spec-based protein biomarker assays.
NEW YORK (GenomeWeb) – New England Peptide and SISCAPA Assay Technologies are collaborating to manufacture and sell stable isotope standard peptides for use in SISCAPA's protein quantification assays.
NEW YORK (GenomeWeb) – Agilent Technologies and SISCAPA Assay Technologies said today that they have signed a non-exclusive agreement to provide complete workflows for targeted protein quantitation.
